Thomas C. Chen

Form D signer

Thomas C. Chen

Chief Executive Officer at NeOnc Technologies

Form D signer

Capital raised by NeOnc Technologies

$27.3M+$5.0M latest round

4 Form D filings · first filed Mar 2025 · Westlake Village, CA

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 4
TEAM ON FILE: 5
FOUNDED: 2023
30D INTEREST: 1 ↗

Career

1 company on file · founded 2023

NeOnc TechnologiesBiotech · Westlake Village, CAsince 2023

Chief Executive Officer

Signatory on NeOnc Technologies's Form D filings · $27.3M raised across 4

Company filings

via EDGAR · Form D for NeOnc Technologies4

DateCompanyFormAmountRole on filing

Jun 10, 2026NeOnc TechnologiesForm D+$5.0MChief Executive Officer

Form DJun 10, 2026 · NeOnc Technologies+$5.0Mas Chief Executive Officer

Jan 29, 2026NeOnc TechnologiesForm D+$10.6MChief Executive Officer

Form DJan 29, 2026 · NeOnc Technologies+$10.6Mas Chief Executive Officer

Mar 26, 2025NeOnc TechnologiesForm D+$1.6MChief Executive Officer

Form DMar 26, 2025 · NeOnc Technologies+$1.6Mas Chief Executive Officer

Mar 10, 2025NeOnc TechnologiesForm D+$10.0MChief Executive Officer

Form DMar 10, 2025 · NeOnc Technologies+$10.0Mas Chief Executive Officer

Overview

Last filing Jun 10, 2026

Thomas C. Chen is on file as Chief Executive Officer at NeOnc Technologies in Westlake Village, CA. NeOnc Technologies has 4 Form D filings on record, $27.3M raised in total. Thomas C. Chen appears as a signatory on the company's filings.

Teammates

NeOnc Technologies · 4

Amir HeshmatpourChief Executive OfficerSigner Amir HeshmatpourDirector Jim DelshadDirector Ming-Fu (Alan) ChiangDirector

Products

NeOnc Technologies · 1

NEO100CNS Therapeutics

NEO100 is a highly purified form of perillyl alcohol (POH) that is administered intranasally. It is currently undergoing Phase II clinical trials specifically targeting patients with recurrent malignant glioma and malignant skull-based meningioma, aiming to provide an innovative solution in the treatment of these challenging CNS tumors.